Alivus Life Sciences Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2025, recommended Final Dividend of Rs. 5 per equity share.
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited), at its meeting held on May 15, 2025, recommended a Final Dividend of Rs. 5 per equity share for the financial year 2024-25. This translates to 250% dividend on the face value of Rs. 2 per share. The dividend is subject to approval from shareholders at the upcoming Annual General Meeting. The company has also made this announcement available on its website.
This is a positive signal for shareholders as it indicates the company is generating enough profits to reward investors. The final dividend will add to investor income once approved, though the actual stock price impact will depend on the company's current market price and overall earnings performance.